Also from this source

You just read:

Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy

News provided by

Ocera Therapeutics, Inc.

Dec 15, 2010, 08:00 EST